Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × INDUSTRY × Hordeolum × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1698 Breast Neoplasms 1260 Carcinoma, Non-Small-Cell Lung 1028 Prostatic Neoplasms 660 Colorectal Neoplasms 604 Neoplasm Metastasis 570 Multiple Myeloma 480 Melanoma 462 Ovarian Neoplasms 397 Lung Neoplasms 394 Lymphoma, Non-Hodgkin 337 Lymphoma 334 Recurrence 329 Leukemia, Myeloid, Acute 325 Pancreatic Neoplasms 319 Carcinoma, Renal Cell 298 Carcinoma, Hepatocellular 251 Leukemia, Lymphocytic, Chronic, B-Cell 242 Stomach Neoplasms 241 Lymphoma, Follicular 230 Head and Neck Neoplasms 212 Leukemia 193 Glioblastoma 193 Small Cell Lung Carcinoma 164 Carcinoma 163 Lymphoma, Large B-Cell, Diffuse 158 Urinary Bladder Neoplasms 156 Uterine Cervical Neoplasms 150 Squamous Cell Carcinoma of Head and Neck 150 Keratosis, Actinic 147

Interventions

Loteprednol Etabonate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00420628 2011-10-07

Pediatric Zylet Safety and Efficacy Study

Bausch & Lomb Incorporated

Phase 4 Completed

108 enrolled 11 charts

Hordeolum, Chalazion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡